CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

International Journal of Cancer

Volumn 117, Issue 4, 2005, Pages 538-550

  Contardi, Elisabetta ^a   Palmisano, Giulio L ^b   Tazzari, Pier Luigi ^c   Martelli, Alberto M ^d   Falà, Federica ^d   Fabbi, Marina ^e   Kato, Tomohiro ^f   Lucarelli, Enrico ^g   Donati, Davide ^g   Polito, Letizia ^d   Bolognesi, Andrea ^d   Ricci, Francesca ^c   Salvi, Sandra ^e   Gargaglione, Vittoria ^a   Mantero, Stefano ^h   Alberghini, Marco ^g   Ferrara, Giovanni Battista ^b   Pistillo, Maria Pia ^e  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^h INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

Apoptosis; CTLA 4; Ligands; Tumors

Indexed keywords

CASPASE 3; CASPASE 8; CD86 ANTIGEN; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LIGAND; RNA;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CELL DIFFERENTIATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG CARCINOMA; OSTEOSARCOMA; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR CELL; TUMOR CELL CULTURE; UTERUS CARCINOMA;

EID: 27144458821     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21155     Document Type: Article

References (50)

1. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987;328:267-70.
2. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
3. Saito T. Negative regulation of T cell activation. Curr Opin Immunol 1998;10:313-21.
4. Kummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
5. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
6. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol 2000;164:5319-27.
7. Chikuma S, Imboden JB, Bluestone JA. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2003;197:129-35.
8. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA, Sharpe AH. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002;32:366-73.
9. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002;196:1335-46.
10. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-10.
11. Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C. The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 1999;5:84-7.
12. Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, Tresser N, Abati A, Fetsch P, Plotz PH. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999;92:161-9.
13. Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, Lefvert AK. Expression of CTLA-4 by human monocytes. Scand J Immunol 2002;55:53-60.
14. Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, Capanni P, Polito L, Ratta M, Pileri S, Piccioli M, Basso G, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003;101:202-9.
15. Tsai AF, Kaufman KA, Walker MA, Karrison TG, Odem RR, Barnes RB, Scott JR, Schreiber JR, Stephenson MD, Ober C. Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage. J Reprod Immunol 1998;40:147-57.
16. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3:807-21.
17. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001;103:449-57.
18. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
19. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
20. Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 1998;77:107-13.
21. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000;12:589-96.
22. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev 2003;192:161-80.
23. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
24. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998;58:5301-4.
25. Martin-Fontecha A, Moro M, Crosti MC, Veglia F, Casorati G, Dellabona P. Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity. J Immunol 2000;164:698-704.
26. Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-14.
27. Briones J, Timmerman JM, Panicalli DL, Levy R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst 2003;95:548-55.
28. Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999;162:4328-35.
29. Meister P, Konrad E, Lob G, Janka G, Keyl W, Sturz H. Osteosarcoma: histologic evaluation and grading. Arch Ortop Trauma Surg 1979;94:91-8.
30. Tazzari PL, Polito L, Bolognesi A, Pistillo MP, Capanni P, Palmisano GL, Lemoli RM, Curti A, Biancone L, Camussi G, Conte R, Ferrara GB, et al. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model. J Immunol 2001;167:4222-9.
31. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999;29:3596-602.
32. Dariavach P, Mattei MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988;18:1901-5.
33. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, Hafler DA, Dorf ME, Gray GS, Reiser H. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992;149:3795-801.
34. Schneider H, Martin M, Agarraberes FA, Yin L, Rapoport I, Kirchhausen T, Rudd CE. Cytolytic T lymphocyte-associated antigen-4 and the TCRζ/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J Immunol 1999;163:1868-79.
35. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996;4:535-43.
36. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987;20:263-72.
37. Cassiede P, Dennis JE, Ma F, Caplan AI. Osteochondrogenic potential of marrow mesenchymal progenitor cells exposed to TGF-beta 1 or PDGF-BB as assayed in vivo and in vitro. J Bone Miner Res 1996;11:1264-73.
38. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
39. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997;64:295-312.
40. Rickard DJ, Kassem M, Hefferan TE, Sarkar G, Spelsberg TC, Riggs BL. Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res 1996;11:312-24.
41. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1:793-801.
42. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996;156:1126-31.
43. Martelli AM, Cappellini A, Tazzari PL, Billi AM, Tassi C, Ricci F, Fala F, Conte R. Caspase-9 is the upstream caspase activated by 8-methoxypsoralen and ultraviolet-A radiation treatment of Jurkat T leukemia cells and normal T lymphocytes. Haematologica 2001;89:471-9.
44. Airoldi I, Lualdi S, Bruno S, Raffaghello L, Occhino M, Gambini C, Pistoia V, Corrias MV. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Br J Cancer 2003;88:1527-36.
45. Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, Lee F, Aruffo AA, Trail PA, Kiener PA. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 2000;165:2903-10.
46. Villinger F, Bostik P, Mayne A, King CL, Genain CP, Weiss WR, Ansari AA. Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules. Immunogenetics 2001;53:315-28.
47. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA, Ke X, Gray GS, Nadler LM. CTLA-4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995;92:811-5.
48. Krummel MF, Allison PJ. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
49. Scheipers P, Reiser H. Fas-independent death of activated CD4+ T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci USA 1998;95:10083-8.
50. Tibbetts MD, Zheng L, Lenardo MJ. The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 2003;4:404-9.